Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
stalevo (lyfjaver) filmuhúðuð tafla 100 mg/25 mg/200 mg
lyfjaver ehf. - entacaponum inn; levodopum inn; carbidopum inn - filmuhúðuð tafla - 100 mg/25 mg/200 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
penovet vet. stungulyf, dreifa 300 .000 a.e./ml
boehringer ingelheim animal health nordics a/s - benzylpenicillinprocainum - stungulyf, dreifa - 300 .000 a.e./ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexametason abcur tafla 1 mg
abcur ab - dexamethasonum fosfat - tafla - 1 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
dexametason abcur tafla 4 mg
abcur ab - dexamethasonum fosfat - tafla - 4 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
diprospan stungulyf, dreifa 5+2 mg/ml
n.v. organon* - betamethasonum dínatríumfosfat; betamethasonum díprópíónat - stungulyf, dreifa - 5+2 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
otrason (flixonase) nefúði, dreifa 50 míkróg/skammt
haleon denmark aps - fluticasonum própíónat - nefúði, dreifa - 50 míkróg/skammt
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
relpax filmuhúðuð tafla 40 mg
upjohn eesv - eletriptanum brómíð - filmuhúðuð tafla - 40 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
tradolan filmuhúðuð tafla 50 mg
g.l. pharma gmbh - tramadolum hýdróklóríð - filmuhúðuð tafla - 50 mg
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
xonvea magasýruþolin tafla 10 mg/10 mg
campuspharma ab - pyridoxinum hýdróklóríð; doxylaminii hýdrógen súkkínat - magasýruþolin tafla - 10 mg/10 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.